Showing 2,541 - 2,560 results of 62,107 for search '(( 5 ((step decrease) OR (we decrease)) ) OR ( 50 ((nn decrease) OR (a decrease)) ))', query time: 1.30s Refine Results
  1. 2541
  2. 2542
  3. 2543
  4. 2544

    Table_1_HIV and HCV screening by non-infectious diseases physicians: can we improve testing and hidden infection rates?.docx by Alejandro G. García-Ruiz de Morales (16445565)

    Published 2023
    “…The willingness to routinely test increased from 5.6 to 22%, whereas not ordering tests decreased from 34.1 to 2.4%. …”
  5. 2545

    Data_Sheet_1_Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.do... by Rebeca Hid Cadena (6956792)

    Published 2019
    “…Our study shows that frequencies of CD80/CD86+ and VISTA+ monocytes were decreased in treated GCA patients only. Moreover, proportions of PD-1+ and VISTA+ Th cells were significantly decreased in GCA patients. …”
  6. 2546

    Mechanistic Insight of Synthesized 1,4-Dihydropyridines as an Antidiabetic Sword against Reactive Oxygen Species by Peter A. Sidhom (14313061)

    Published 2022
    “…Also, compound <b>8b</b> decreased blood glucose by α-glucosidase inhibition (IC<sub>50</sub> = 4.48 ± 0.32 μM), compared to acarbose (7.40 ± 0.41 μM), based selectively on the plasma window of <b>8b</b>. …”
  7. 2547
  8. 2548

    Image_5_Resting Energy Expenditure and Body Composition in Children and Adolescents With Genetic, Hypothalamic, Medication-Induced or Multifactorial Severe Obesity.tif by Ozair Abawi (8816267)

    Published 2022
    “…Mean REE% was higher in children with non-syndromic genetic obesity (107.4% ± 12.7) and lower in children with hypothalamic obesity (87.6% ± 14.2) compared to multifactorial obesity (100.5% ± 12.6, both p<0.01). In 9 children with pseudohypoparathyroidism type 1a, mean REE% was similar (100.4 ± 5.1). …”
  9. 2549
  10. 2550
  11. 2551
  12. 2552
  13. 2553

    Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner by Khondoker Alam (1443499)

    Published 2017
    “…Pretreatment with bortezomib (50–250 nM, 2–7 h) significantly decreased transport of [<sup>3</sup>H]CCK-8, a specific OATP1B3 substrate, in HEK293-OATP1B3 and human sandwich-cultured hepatocytes (SCH). …”
  14. 2554

    Bcl-xL protein levels were decreased in response to siRNA transfection in A549, SK-LU1 and NP-69 cells. by Norahayu Othman (495150)

    Published 2013
    “…<p>(<b>A</b>) Western blot indicating a significant decrease in Bcl-xL protein levels in comparison to non-transfected cells 48 h post-transfection. …”
  15. 2555

    Methodology. by Scott John (228011)

    Published 2024
    “…Upon binding of lactate YFP and CFP move farther apart, the intensity of YFP fluorescence decreases while that of CFP increases. This leads to a decrease in the YFP/CFP FRET ratio. …”
  16. 2556

    (A) The proportion of fast MyHC myotubes is decreased in Igf-2 deficient mice (maternal disomy Chromosome 7 - MatDi) at E14 by Deborah Merrick (54928)

    Published 2011
    “…<p><b>Copyright information:</b></p><p>Taken from "A role for Insulin-like growth factor 2 in specification of the fast skeletal muscle fibre"</p><p>http://www.biomedcentral.com/1471-213X/7/65</p><p>BMC Developmental Biology 2007;7():65-65.…”
  17. 2557
  18. 2558
  19. 2559

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
  20. 2560

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”